1	Amgen	_	NNP	_	_	3	SBJ	_	_
2	Inc.	_	NNP	_	_	1	POSTHON	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	its	_	PRP$	_	_	6	NMOD	_	_
5	second-quarter	_	JJ	_	_	6	NMOD	_	_
6	earnings	_	NNS	_	_	7	SBJ	_	_
7	increased	_	VBD	_	_	3	OBJ	_	_
8	more	_	RBR	_	_	10	AMOD	_	_
9	than	_	IN	_	_	10	AMOD	_	_
10	tenfold	_	RB	_	_	7	ADV	_	_
11	to	_	TO	_	_	7	DIR	_	_
12	$	_	$	_	_	11	PMOD	_	_
13	3.9	_	CD	_	_	12	DEP	_	_
14	million	_	CD	_	_	12	DEP	_	_
15	,	_	,	_	_	12	P	_	_
16	or	_	CC	_	_	12	COORD	_	_
17	22	_	CD	_	_	18	NMOD	_	_
18	cents	_	NNS	_	_	16	CONJ	_	_
19	a	_	DT	_	_	20	NMOD	_	_
20	share	_	NN	_	_	18	ADV	_	_
21	,	_	,	_	_	7	P	_	_
22	due	_	JJ	_	_	7	PRP	_	_
23	to	_	TO	_	_	22	PMOD	_	_
24	increased	_	VBN	_	_	25	NMOD	_	_
25	sales	_	NNS	_	_	23	PMOD	_	_
26	of	_	IN	_	_	25	NMOD	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	company	_	NN	_	_	32	NMOD	_	_
29	's	_	POS	_	_	28	SUFFIX	_	_
30	new	_	JJ	_	_	32	NMOD	_	_
31	antianemia	_	JJ	_	_	32	NMOD	_	_
32	drug	_	NN	_	_	26	PMOD	_	_
33	for	_	IN	_	_	32	NMOD	_	_
34	kidney	_	NN	_	_	35	NMOD	_	_
35	patients	_	NNS	_	_	33	PMOD	_	_
36	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	7	NMOD	_	_
2	Thousand	_	NNP	_	_	5	AMOD	_	_
3	Oaks	_	NNP	_	_	5	AMOD	_	_
4	,	_	,	_	_	5	P	_	_
5	Calif.-based	_	JJ	_	_	7	NMOD	_	_
6	biotechnology	_	NN	_	_	7	NMOD	_	_
7	company	_	NN	_	_	8	SBJ	_	_
8	reported	_	VBD	_	_	0	ROOT	_	_
9	a	_	DT	_	_	12	NMOD	_	_
10	97	_	CD	_	_	11	AMOD	_	_
11	%	_	NN	_	_	12	NMOD	_	_
12	increase	_	NN	_	_	8	OBJ	_	_
13	in	_	IN	_	_	12	LOC	_	_
14	revenue	_	NN	_	_	13	PMOD	_	_
15	to	_	TO	_	_	12	NMOD	_	_
16	$	_	$	_	_	15	PMOD	_	_
17	42.5	_	CD	_	_	16	DEP	_	_
18	million	_	CD	_	_	16	DEP	_	_
19	for	_	IN	_	_	8	ADV	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	quarter	_	NN	_	_	19	PMOD	_	_
22	ended	_	VBN	_	_	21	APPO	_	_
23	Sept.	_	NNP	_	_	22	TMP	_	_
24	30	_	CD	_	_	23	NMOD	_	_
25	.	_	.	_	_	8	P	_	_

1	In	_	IN	_	_	7	TMP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	year-ago	_	JJ	_	_	4	NMOD	_	_
4	period	_	NN	_	_	1	PMOD	_	_
5	,	_	,	_	_	7	P	_	_
6	Amgen	_	NNP	_	_	7	SBJ	_	_
7	reported	_	VBD	_	_	0	ROOT	_	_
8	net	_	JJ	_	_	9	NMOD	_	_
9	income	_	NN	_	_	7	OBJ	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	$	_	$	_	_	10	PMOD	_	_
12	320,000	_	CD	_	_	11	NMOD	_	_
13	,	_	,	_	_	11	P	_	_
14	or	_	CC	_	_	11	COORD	_	_
15	two	_	CD	_	_	16	NMOD	_	_
16	cents	_	NNS	_	_	14	CONJ	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	16	ADV	_	_
19	,	_	,	_	_	9	P	_	_
20	on	_	IN	_	_	9	NMOD	_	_
21	revenue	_	NN	_	_	20	PMOD	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	$	_	$	_	_	22	PMOD	_	_
24	21.5	_	CD	_	_	23	DEP	_	_
25	million	_	CD	_	_	23	DEP	_	_
26	.	_	.	_	_	7	P	_	_

1	For	_	IN	_	_	8	ADV	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	six	_	CD	_	_	4	NMOD	_	_
4	months	_	NNS	_	_	1	PMOD	_	_
5	,	_	,	_	_	8	P	_	_
6	the	_	DT	_	_	7	NMOD	_	_
7	company	_	NN	_	_	8	SBJ	_	_
8	reported	_	VBD	_	_	0	ROOT	_	_
9	a	_	DT	_	_	13	NMOD	_	_
10	more	_	JJR	_	_	13	NMOD	_	_
11	than	_	IN	_	_	10	AMOD	_	_
12	sixfold	_	JJ	_	_	10	AMOD	_	_
13	increase	_	NN	_	_	8	OBJ	_	_
14	in	_	IN	_	_	13	LOC	_	_
15	earnings	_	NNS	_	_	14	PMOD	_	_
16	to	_	TO	_	_	13	NMOD	_	_
17	$	_	$	_	_	16	PMOD	_	_
18	4.7	_	CD	_	_	17	DEP	_	_
19	million	_	CD	_	_	17	DEP	_	_
20	,	_	,	_	_	17	P	_	_
21	or	_	CC	_	_	17	COORD	_	_
22	26	_	CD	_	_	23	NMOD	_	_
23	cents	_	NNS	_	_	21	CONJ	_	_
24	a	_	DT	_	_	25	NMOD	_	_
25	share	_	NN	_	_	23	ADV	_	_
26	,	_	,	_	_	13	P	_	_
27	from	_	IN	_	_	13	NMOD	_	_
28	$	_	$	_	_	27	PMOD	_	_
29	625,000	_	CD	_	_	28	NMOD	_	_
30	,	_	,	_	_	28	P	_	_
31	or	_	CC	_	_	28	COORD	_	_
32	four	_	CD	_	_	33	NMOD	_	_
33	cents	_	NNS	_	_	31	CONJ	_	_
34	a	_	DT	_	_	35	NMOD	_	_
35	share	_	NN	_	_	33	ADV	_	_
36	a	_	DT	_	_	37	NMOD	_	_
37	year	_	NN	_	_	38	AMOD	_	_
38	ago	_	RB	_	_	27	TMP	_	_
39	.	_	.	_	_	8	P	_	_

1	Revenue	_	NN	_	_	2	SBJ	_	_
2	rose	_	VBD	_	_	0	ROOT	_	_
3	77	_	CD	_	_	4	NMOD	_	_
4	%	_	NN	_	_	2	EXT	_	_
5	to	_	TO	_	_	2	DIR	_	_
6	$	_	$	_	_	5	PMOD	_	_
7	72.6	_	CD	_	_	6	DEP	_	_
8	million	_	CD	_	_	6	DEP	_	_
9	,	_	,	_	_	2	P	_	_
10	from	_	IN	_	_	2	DIR	_	_
11	last	_	JJ	_	_	12	NMOD	_	_
12	year	_	NN	_	_	10	PMOD	_	_
13	's	_	POS	_	_	12	SUFFIX	_	_
14	$	_	$	_	_	12	NMOD	_	_
15	41	_	CD	_	_	14	DEP	_	_
16	million	_	CD	_	_	14	DEP	_	_
17	.	_	.	_	_	2	P	_	_

